亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

南京克萊森醫(yī)藥化工有限公司  

普瑞巴林中間體，替卡格雷中間體，達(dá)比加群酯中間體，羅匹尼羅中間體，利克飛龍中間體，阿扎那韋中間體，拉帕替尼中間體，埃羅替尼中間體，伐侖克林中間體，地瑞那韋中間體，阿替美唑中間體，依替米貝中間體
搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
  • 聯(lián)系人：徐罡
  • 電話：025-83172646
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
首頁(yè) > 供應(yīng)產(chǎn)品 > 拉帕替尼中間體27329-70-0
拉帕替尼中間體27329-70-0
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 江蘇南京市付款后3天內(nèi)
品牌 5-甲醛基呋喃-2-硼酸
型號(hào) 27329-70-0
規(guī)格 27329-70-0
過(guò)期 長(zhǎng)期有效
更新 2012-05-31 16:55
 
詳細(xì)信息

2-Formylfuran-5-boronic acid  5-甲醛基呋喃-2-硼酸                   cas 27329-70-0
Name of product：2-Formylfuran-5-boronic acid
CAS No：27329-70-0
Formula：C5H5BO4
Molecular Weight：139.90
©2025 南京克萊森醫(yī)藥化工有限公司 版權(quán)所有   技術(shù)支持：化工網(wǎng)   訪問(wèn)量:9969  
 
主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |